Supernus Pharmaceuticals | SUPN - Pre Tax Profit


Supernus Pharmaceuticals reported $-57.65M in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
ANI Pharmaceuticals USD 40.22M 8.74M Mar/2026
Aurora Cannabis CAD 11.41M 12.99M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Canopy Growth CAD -157.96M 95.71M Mar/2026
Cara Therapeutics USD -6.8M 1.9M Mar/2026
Corcept Therapeutics USD -44.72M 54.62M Mar/2026
Eisai JPY 25.28B 33.22B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Novo Nordisk DKK 33.8B 3.23B Jun/2025
Pacira USD 5M 4.43M Mar/2026
Perrigo USD 105.4M 513.9M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
Supernus Pharmaceuticals USD -57.65M 51.7M Jun/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026